Axoltis pharma
French tech company | Builders Republic
About
Clinical-stage biotech developing peptide-based treatments for neurodegenerative and neurotrauma disorders — built on a peptide derived from a brain-development protein that repairs the blood-brain barrier and protects neurons, with a lead program in Phase 2 for amyotrophic lateral sclerosis (ALS).
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Series A
- Founded
- 2003
- City
- CLERMONT-FERRAND
- Region
- Auvergne-Rhône-Alpes
- Tracked rounds
- 1
- Amount raised
- 18 M€ raised since 2020
Funding rounds
- Series A — 2025